Treatment Goals and Guidelines for CSU

Video content above is prompted by the following:

• What are the factors that shape the development of treatment goals, both for patients and physicians?
• What do international guidelines currently recommend for therapeutic approach? (Zuberbier, J Allergy Clin Immunol, 2022)
  • First-line treatment: antihistamine
  • Patients with insufficient response, updosing should be considered, via shortening interview and/or increasing dosage
  • Second-line treatment: omalizumab; start with 300 mg/4 weeks
  • Third-line treatment: cyclosporine
  • General recommendation to step-up and step-down treatment based on levels of disease control